"Company","Parent Company","Penalty Amount","Subtraction From Penalty","Penalty Amount Adjusted For Eliminating Multiple Counting","Penalty Year","Penalty Date","Offense Group","Primary Offense","Secondary Offense","Description","Level of Government","Action Type","Agency","Civil/Criminal","Prosecution Agreement","Court","Case ID","Private Litigation Case Title","Lawsuit Resolution","Facility State","City","Address","Zip","NAICS Code","NAICS Translation","HQ Country of Parent","HQ State of Parent","Ownership Structure","Parent Company Stock Ticker","Major Industry of Parent","Specific Industry of Parent","Info Source","Notes"
"Daiichi Sankyo Inc.","Daiichi Sankyo","$39,000,000","$0","$39,000,000","2015","20150109","government-contracting-related offenses","False Claims Act and related","kickbacks and bribery","Daiichi Sankyo Inc., a global pharmaceutical company with its U.S. headquarters in New Jersey, agreed to pay the United States and state Medicaid programs $39 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce physicians to prescribe Daiichi drugs.","federal","agency action","Justice Department Civil Division","civil","","","","","","","","","","","","Japan","","publicly traded","","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/daiichi-sankyo-inc-agrees-pay-39-million-settle-kickback-allegations-under-false-claims-act",""
"Daiichi Sankyo","Daiichi Sankyo","$8,200,000","$0","$8,200,000","2016","20160211","employment-related offenses","employment discrimination","gender discrimination","The settlement amount included $3 million for legal fees and costs.","federal","private litigation","","civil","","Northern District of California","4:13-cv-00581","Wellens v. Daiichi Sankyo","settlement","","","","","","","Japan","","publicly traded","","pharmaceuticals","pharmaceuticals","https://www.clearinghouse.net/detail.php?id=12924&search=source%7Cgeneral%3BcaseName%7Cwellens%3Borderby%7CfilingYear%3B",""
"Daiichi Pharmaceutical","Daiichi Sankyo","$4,340,100","$0","$4,340,100","2000","20001011","competition-related offenses","price-fixing or anti-competitive practices","","Six international vitamin companies agreed to pay a total of $255 million to settle multistate litigation accusing them of conspiring to fix prices. The settlement agreement linked below lists the percentages of the total applicable to each defendant; they were used to determine the penalty amounts in the individual company entries here. The companies reached a separate $85 million agreement with California. These are covered in separate Violation Tracker entries.","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","Japan","","publicly traded","","pharmaceuticals","pharmaceuticals","http://app3.naag.org/antitrust/search/viewCivilLitigation.php?trans_id=182",""
"Daiichi Pharmaceutical","Daiichi Sankyo","$1,446,700","$0","$1,446,700","2000","20001010","competition-related offenses","price-fixing or anti-competitive practices","","The California Attorney General reached an $85 million with six major vitamin producers to resolve international price-fixing allegations. This was separate from a $255 million settlement the companies reached with a group of other states. The California announcement did not indicate how the $85 million would be apportioned among the defendants. We assume here that it divided up according to the same percentages used in the larger settlement.","state","agency action","California Attorney General","civil","","","","","","California","","","","","","Japan","","publicly traded","","pharmaceuticals","pharmaceuticals","https://www.oag.ca.gov/news/press-releases/attorney-general-lockyer-announces-80-million-antitrust-settlement-involving",""
"Daiichi Pharmaceutical","Daiichi Sankyo","$111,167","$0","$111,167","2002","20020904","competition-related offenses","price-fixing or anti-competitive practices","","Hoffman-La Roche Inc. and Roche Vitamins Inc.; BASF Corporation; Aventis Animal Nutrition S.A., formerly Rhone-Poulenc Animal Nutrition S.A.; Takeda Chemical Industries, Ltd.; Eisai Co., Ltd.; and Daiichi Pharmaceutical Co., Ltd. agreed to jointly pay $667,000 in settlement of allegations they enaged in price fixing of vitamins. The Commonwealth of Massachusetts did not participate in the multistate settlement in October 2000 and instead made claims for antitrust damages under the Massachusetts Consumer Protection Act. The announcement did not indicate how much each company would pay. Here we assume the amount was divided equally among them.","state","agency action","Massachusetts Attorney General","civil","","","","","","Massachusetts","","","","","","Japan","","publicly traded","","pharmaceuticals","pharmaceuticals","https://web.archive.org/web/20020928141823/http://www.ago.state.ma.us/press_rel/vitamins.asp",""
"Daiichi Sankyo, Inc.","Daiichi Sankyo","$39,000,000","$0","$39,000,000","2015","20150316","government-contracting-related offenses","False Claims Act and related","kickbacks and bribery","Daiichi Sankyo, Inc. agreed to pay $39 million to settle multistate litigation alleging that it violated the False Claims Act by using lavish meals and speaker programs to improperly induce physicians to prescribe the drugs Azor, Benicar, Tribenzor and Welchol. ","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","Japan","","publicly traded","","pharmaceuticals","pharmaceuticals","https://web.archive.org/web/20160820071805/http://ag.ny.gov/press-release/ag-schneiderman-announces-kickback-settlement-pharma-manufacturer-daiichi-sankyo",""
"Daiichi Sankyo Inc.","Daiichi Sankyo","$300,000,000","$0","$300,000,000","2017","20170801","safety-related offenses","product safety violation","","Daiichi Sankyo agreed to pay $300 million to settle multi-district litigation alleging that the blood pressure drug Benicar caused gastrointestinal problems.","federal","private litigation","","civil","","District of New Jersey","MDL No. 2606","In Re: Benicar (Olmesartan) Products Liability Litigation","settlement","","","","","","","Japan","","publicly traded","","pharmaceuticals","pharmaceuticals","https://www.law360.com/articles/950057/daiichi-forest-reach-300m-settlement-in-benicar-mdl",""
